Findings from the current study demonstrate that over half of chronic HF patients in the DIG trial had severe and more advanced disease as evidenced by the presence of NYHA III–IV symptoms, LVEF <25%, ...

"In the DIG trial, published in 1997, digoxin had a neutral effect on the primary endpoint of mortality, but a 28% reduction in heart failure hospitalizations (a secondary endpoint) was observed.

A low dose of digoxin ensures that people with heart failure are hospitalized and die less frequently. This emerges from three studies led by UMCG cardiologists Dirk Jan van Veldhuisen, Kevin Damman, ...

The use of digoxin for hospitalized patients with heart failure with reduced ejection fraction (HFrEF) has garnered some support with the publication of a new study suggesting that discontinuation of ...

Wearable device data could predict New York Heart Association functional class similarly to clinical measures and six-minute walk test. HealthDay News — For patients with atrial fibrillation, digoxin ...

Prognosis in Patients With Sentinel Node–Positive Melanoma Is Accurately Defined by the Combined Rotterdam Tumor Load and Dewar Topography Criteria Two thousand one hundred forty-four of 104,648 women ...

Research in mice has shown how a drug that is already used to treat heart disease can reverse obesity in mice, with no apparent side effects. The study, by scientists at the Spanish National Cancer ...

Heart drugs called digitalis glycosides, which include digoxin and digitoxin, have been used for centuries, but their place in the modern treatment of heart failure remains undefined. Results were ...